Skip to main content


  • Research
  • Open Access
  • Open Peer Review

Treatment of hyperprolactinemia: a systematic review and meta-analysis

  • 1, 2Email author,
  • 1,
  • 1,
  • 1, 3,
  • 2,
  • 4,
  • 1, 5,
  • 1,
  • 6,
  • 1,
  • 1,
  • 8,
  • 7,
  • 1, 4 and
  • 1, 3
Systematic Reviews20121:33

  • Received: 30 November 2011
  • Accepted: 24 July 2012
  • Published:
Open Peer Review reports



Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to provide evidence-based recommendations for practitioners. Through this review, we aimed to compare efficacy and adverse effects of medications, surgery and radiotherapy in the treatment of hyperprolactinemia.


We searched electronic databases, reviewed bibliographies of included articles, and contacted experts in the field. Eligible studies provided longitudinal follow-up of patients with hyperprolactinemia and evaluated outcomes of interest. We collected descriptive, quality and outcome data (tumor growth, visual field defects, infertility, sexual dysfunction, amenorrhea/oligomenorrhea and prolactin levels).


After review, 8 randomized and 178 nonrandomized studies (over 3,000 patients) met inclusion criteria. Compared to no treatment, dopamine agonists significantly reduced prolactin level (weighted mean difference, -45; 95% confidence interval, -77 to −11) and the likelihood of persistent hyperprolactinemia (relative risk, 0.90; 95% confidence interval, 0.81 to 0.99). Cabergoline was more effective than bromocriptine in reducing persistent hyperprolactinemia, amenorrhea/oligomenorrhea, and galactorrhea. A large body of noncomparative literature showed dopamine agonists improved other patient-important outcomes. Low-to-moderate quality evidence supports improved outcomes with surgery and radiotherapy compared to no treatment in patients who were resistant to or intolerant of dopamine agonists.


Our results provide evidence to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine. Radiotherapy and surgery are useful in patients with resistance or intolerance to dopamine agonists.


  • Treatment
  • Hyperprolactinemia
  • Macroprolactinoma
  • Microprolactinoma


Hyperprolactinemia is the most common disorder of the hypothalamic-pituitary axis. Patients typically present with hypogonadism, infertility or, in the case of macroadenomas, symptoms related to mass effect (headache and visual field defects).

In general, treatment of hyperprolactinemia, secondary to pituitary macroadenoma, is accepted as necessary. Medications in the form of dopamine agonists are the first line of treatment, with surgery and radiotherapy reserved for refractory and medication-intolerant patients [1]. The primary aim of treatment in patients with pituitary macroadenoma is to control compressive effects of the tumor, including compression of optic chiasm, with a secondary goal to restore gonadal function. However, indications and modalities of treatment of hyperprolactinemia due to pituitary microadenomas are less well defined [1]. Commonly cited indications for treatment of microprolactinomas include infertility, hypogonadism, prevention of bone loss and bothersome galactorrhea [1, 2]. Treatment with dopamine agonists can restore normal prolactin levels and gonadal function. Dopamine agonists have been associated with various adverse effects including nausea, vomiting, psychosis and dyskinesia. However, the choice of which dopamine agonist is most efficacious and produces the least adverse effects is unclear.

To provide evidence-based recommendations to practicing clinicians facing these common therapeutic dilemmas, we conducted a systematic review and meta-analyses of the literature to evaluate outcomes and adverse effects with medications, surgery and radiotherapy in hyperprolactinemic patients. Outcomes of interest include prolactin levels, tumor size, and persistent hyperprolactinemia and patient-important outcomes, including visual disturbances, fertility, sexual dysfunction and galactorrhea,


The results are reported according to the PRISMA statement (Preferred reporting items for systematic reviews and meta-analyses) [3]. We used the relevant components of the Ottawa-Newcastle tool (whether cohorts represent clinical practice, blinding of outcome assessment, analysis adjustment for confounders, and adequacy of follow-up) [4] and the Cochrane risk of bias tool (extent of blinding, allocation concealment, and funding) to evaluate the quality of observational and randomized trials, respectively. Summary judgments about the quality of evidence for each outcome followed the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework (Additional file 1: Tables 2–4) [5].

Study eligibility

Eligible studies provided longitudinal follow-up data of cohorts of patients with hyperprolactinemia, that is, observational cohort studies or randomized controlled trials (RCTs). The outcomes of interest were tumor size, visual field defects, prolactin levels, galactorrhea, infertility, hypogonadism (amenorrhea/oligomenorrhea and low libido for premenopausal women, low libido or erectile dysfunction for men), bone density loss and fragility fracture rates, quality of life, and treatment adverse effects. We assumed author reports of “irregular menses” to mean amenorrhea or oligomenorrhea unless otherwise specified. We included studies with follow-up duration of at least six months and studies of at least 10 subjects. We did not impose any language restrictions.

Search strategy

We sought articles addressing hyperprolactinemia or prolactin-secreting tumors that were treated by dopamine agonists, surgery or radiotherapy, which focused on outcomes from those treatments. The search concepts of hyperprolactinemia, outcomes of interest (specific sequelae of amenorrhea/oligomenorrhea, sexual dysfunction, vision disorders, cranial nerve disorders and bone disorders), treatments and study design (observational longitudinal studies or RCTs) were represented in the search strategy using database-specific controlled vocabulary. We searched in Ovid MEDLINE, Ovid EMBASE and the Ovid Cochrane Library, ISI Web of Science and Scopus from inception through September 2009. The search was updated on 15 December 2011. The complete search strategy was done with the help of an experienced research librarian and is available in the Additional file 1: Appendix.

Study selection

Study selection and data extraction procedures were conducted by pairs of reviewers working independently until adequate agreement (kappa ≥ 0.90) was obtained; then the process was conducted by single reviewers. First, eligibility criteria were applied to titles and abstracts, and potentially eligible studies were retrieved in full text. Then, eligibility criteria were applied to the full report. Disagreements were noted and resolved by discussion and consensus, erring on inclusion. We extracted descriptive data about enrolled patients, any treatment provided, study quality measures and outcome data from each study. Both study selection and data extraction were conducted using web-based software (Distiller SR, Ottawa, ON, Canada).

Statistical analysis

The effect size and the associated measures of precision were estimated from each study (relative risk (RR) for dichotomous outcomes, weighted mean difference (WMD) for continuous outcomes, and event rate for uncontrolled studies).

Effect sizes were pooled across studies using a random effects meta-analytical model [6]. Heterogeneity was assessed using the I2 statistic, which represents the proportion of between-study differences that are not attributable to chance or random error [7]. I2 values of <25%, 25 to 50% and >50% indicate mild, moderate and substantial heterogeneity, respectively. When meta-analysis includes less than three studies, the I2 is not calculable and is not reported. A priori planned subgroup interactions were based on sex and size of tumor (macro- vs. microprolactinomas). Median and range of event rates were estimated from uncontrolled cohort studies or case series that did not provide sufficient data for meta-analysis. All analyses were completed using Comprehensive Meta Analysis Version 2.2, Biostat, Englewood NJ (2005).


Literature search revealed 2,103 potentially relevant references, of which 189 were included (Figure 1). The description, quality assessment and bibliography of the studies are available in the Additional file 1: Appendix.
Figure 1
Figure 1

Study selection process.

Figure 2
Figure 2

Bromocriptine vs. Cabergoline: prolactin levels.

Figure 3
Figure 3

Bromocriptine vs. Cabergoline: clinical outcomes.

Twenty-nine studies were controlled (that is, two arms allowing for comparative analysis) (Additional file 1: Table 1), whereas 157 were uncontrolled (that is, the entire cohort received the same intervention allowing the estimation of event rates but no comparative analysis). We contacted the authors of the comparative studies via e-mail if possible and by postal mail if no e-mail was available; 20 authors replied, of which 15 confirmed or corrected study data.

Study quality

The quality of the observational studies was limited, with no blinding of outcome assessment and poor reporting of adjustments for confounders or other prognostic variables (Additional file 1: Tables 2 and 3). The quality of the eight RCTs [814] was fair (allocation was concealed in five; patients were blinded to assignment in six RCTs, caregivers in five) (Additional file 1: Table 4).

Patients treated with dopamine agonists

A large body of noncomparative cohort studies supported the use of dopamine agonists in patients with hyperprolactinemia. Those studies included: bromocriptine (n = 39); cabergoline (n = 26); and quinagolide (CV 205-502) (n = 15), which is not approved in the US. Bromocriptine studies had the longest follow-up (exceeding 10 years) and showed consistent benefits on several patient-important outcomes and surrogate outcomes (Additional file 1: Table 5A). Comparing across studies, 68% (median %) of patients treated with bromocriptine had normalization of prolactin levels and 62% experienced a reduction in tumor size. Bromocriptine also successfully treated other major outcomes, including 86% of patients with galactorrhea, 78% with amenorrhea, 67% with sexual dysfunction, 67% with visual field defects and 53% of patients with infertility. Studies of cabergoline and quinagolide showed similar results (Additional file 1: Tables 5B, C). In three observational studies that followed patients from 7 to 12 months, long-acting forms of bromocriptine were found to be as efficacious as the short-acting forms (Additional file 1: Table 5D). Other dopamine agonists typically used for other conditions, such as Parkinson’s disease, were also used in this setting; namely, pergolide, lisuride, and roxindol (Additional file 1: Table 5E), with comparable findings.

A smaller body of evidence offers comparative effectiveness data from observational studies and eight RCTs. Forest plots depicting the results of these meta-analyses are in Additional file 1: Figures 1A-5B. The results are presented by comparison.

· Bromocriptine vs. Cabergoline (Figures 2 and 3): Six observational studies and three randomized trials compared bromocriptine to cabergoline. Bromocriptine was less effective than cabergoline in reducing the risk of persistent hyperprolactinemia (RR, 2.88; 95% CI, 2.20 to 3.74; I2 = 0%), amenorrhea/oligomenorrhea (RR, 1.85; 95% CI, 1.40 to 2.36), and galactorrhea (RR, 3.41; 95% CI, 1.9 to 5.84). There were no significant differences between the two drugs in terms of overall change in prolactin level or other patient-important outcomes.

· Bromocriptine vs. Quinagolide: Two observational studies and four RCTs compared quinagolide to bromocriptine. There were no significant differences between these agents across all outcomes reviewed (Additional file 1: Figures 1A and 1B).

· Dopamine agonists compared to no treatment: Three observational studies and one RCT compared dopamine agonists to no treatment. Dopamine agonists significantly reduced prolactin level (WMD, -45; 95% CI, -77 to -11) and the risk of persistent hyperprolactinemia (RR, 0.9; 95% CI, 0.81 to 0.99) but not other patient-important outcomes (Additional file 1: Figures 2A and 2B).

· Comparison of dopamine agonists vs. surgery and combinations thereof: Additional file 1: Figures 3-5B depict comparisons between surgery vs. dopamine agonists, dopamine agonists vs. dopamine agonists + surgery, and surgery vs. surgery + dopamine agonists. The only significant difference among these comparisons was dopamine agonists were more effective in reducing the risk of persistent hyperprolactinemia compared to surgery alone.

The quality of evidence in this comparison for all outcomes is very low due to methodological limitations of included studies and the serious imprecision of meta-analytic estimates that include both trivial and large effects. Subgroup analyses for these comparisons (Additional file 1: Table 6) did not reveal a significant interaction based on sex or tumor size (macro- vs. microprolactinoma).

Patients treated with other modalities

Other treatments, such as radiotherapy, surgery and combinations of treatments were evaluated in an uncontrolled series of patients. Meta-analysis was not conducted due to the significant clinical heterogeneity in terms of patient characteristics and symptomatology as well as the heterogeneity of study settings, design and follow-up duration.

Radiotherapy was evaluated in eight studies with follow-up of at least two years. In patients with medically and surgically refractory prolactinomas, radiotherapy produced a reduction in prolactin levels in nearly all patients and normalization in over a quarter of patients with low complication rates (Additional file 1: Table 7A). External and implanted radiotherapy methods were also used in conjunction with dopamine agonists and resulted in significant improvement in prolactin levels, visual symptoms and fertility (four studies with follow-up of between 12 and 140 months, Additional file 1: Table 7B).

Trans-sphenoidal surgery for pituitary adenomas was evaluated in 27 uncontrolled studies (Additional file 1: Table 7C) and was found to be effective in normalizing prolactin levels and resolving symptoms. Patients opting for this approach had often failed other management options and may have had a worse prognosis that was independent of the treatment; this selection bias may underestimate the effectiveness of surgery. In five studies, a combination of surgery and dopamine agonists achieved high rates of prolactin normalization and had relatively low rates of recurrence (Additional file 1: Table 7D). In two studies (Additional file 1: Table 7E), surgery combined with radiotherapy was also seen to be effective.

Adverse effects

Commonly reported side effects for all dopamine agonists included nausea, dizziness, postural hypotension and headache. In studies comparing cabergoline and bromocriptine, side effects were less frequent and milder with cabergoline compared to bromocriptine. In one study, 18%, 18%, 9% and 3% of patients experienced nausea, hypotension, headache and vomiting, respectively, compared with 44 21%, 27% and 20% in patients receiving bromocriptine [Motazedian, 2010, #105]. Bahceci found an overall side effect rate of 2.5% for cabergoline versus 15.3% for bromocriptine [Bahceci, 2010, #103]. Another study found a 29% overall side effect rate for cabergoline vs. 70% with bromocriptine, and that cabergoline side effects were more mild, self-limited, and did not require intervention, compared to bromocriptine side effects which required dose reduction and intervention in 29% of cases [De Rosa, 1998, #104]. Non-comparative studies revealed similar findings with the most common side effects of dopamine agonists being nausea, vomiting, headache, hypotension, with rare side effects of rhinorrhea and hypotonia. Adverse effects reported with transsphenoidal surgery included cerebrospinal fluid leak, diabetes insipidus, rhinorrhea and hypopituitarism, while radiotherapy was associated with nausea, headache, visual disturbances and hearing loss.

Pregnancy studies

Twenty studies followed pregnant women and their offspring from 6 months up to 12 years (Additional file 1: Table 7F). A fairly consistent finding was that there was no significant increase in the risk of obstetric complications, miscarriages, fetal malformation or other pregnancy outcomes, even if they had been treated with dopamine agonists to induce ovulation. The quality of this evidence is low considering the lack of contemporary untreated control groups in most studies or the enrollment of nonconsecutive samples of patients.


The two most commonly prescribed drugs in the treatment of hyperprolactinemia are bromocriptine and cabergoline. Both medications are dopamine receptor agonists and share many characteristics and adverse effects, such as headache, nausea and vomiting, among others, though frequency and severity of adverse effects appears to be less in cabergoline compared to bromocriptine. Previous concerns about valvular heart disease [15, 16] with the use of these agents have largely been disproved by more recent reports [1719]. Our review demonstrated that cabergoline was significantly better than bromocriptine in decreasing the risks of persistent hyperprolactinemia, amenorrhea/oligomenorrhea and galactorrhea. Frequency of dosing may also affect treatment decisions as cabergoline is dosed twice weekly, whereas bromocriptine is given daily. However, cabergoline costs at least twice as much as bromocriptine and was not found to be superior in other outcomes. Though both drugs have been found to be safe in pregnancy, the number of reports studying bromocriptine in pregnancy far exceeds that of cabergoline in pregnancy.

A large body of moderate quality evidence from observational studies supports the use of dopamine agonists to normalize prolactin levels and resolve the symptoms related to mass effect and elevated prolactin levels. The large treatment effect of dopamine agonists, the potential dose response effect, biological plausibility, temporality between treatment and effect, consistency across studies, settings and methods, and coherence (consistency across agents within the same class), strongly support the effectiveness of these treatment agents in reducing prolactin levels and improving symptoms [20]. In addition, the recurrence of hyperprolactinemia after withdrawal of dopamine agonists strengthens the inference about causality (that is, challenge-rechallenge phenomenon). Clinicians using these medications are well aware of potential adverse effects that sometimes limit use, which include nausea, vomiting, psychosis and dyskinesia, among others.

Efficacy of surgery and radiotherapy in selected patients is also substantiated, although by low-to-moderate quality evidence at higher risk of bias. Radiotherapy and surgery appear to be efficacious in patients with resistance or intolerance to dopamine agonists. However, surgery as a primary therapy has also been described in a recent consecutive series of 212 patients with prolactinomas [21]. This study reports high short-term remission rates, particularly in patients with microadenomas and cystic tumors. Besides the usual surgical risks, hypopituitarism is a potential long-term effect of both radiotherapy and surgery and should be discussed with patients as part of the decision-making process.

Comparison with previous reviews, strengths and limitations

Only a few previous systematic reviews have been published in this field, and to the best of our knowledge, this is the first to comprehensively address the efficacy questions outlined in our protocol. Our work is also referenced as unpublished data in the 2011 Endocrine Society Clinical Practice Guideline: Diagnosis and Treatment of Hyperprolactinemia [22]. Our results are similar to other reviews, including Dekkers’ meta-analysis of the sustainability of normoprolactinemia after treatment withdrawal, which found recurrences in a substantial proportion of patients [23], and Dos Santos Nunes’ systematic review and meta-analysis of four randomized controlled trials, which demonstrated that normalization of prolactin levels and menstruation favored cabergoline compared to bromocriptine [24].

The strengths of our review include the comprehensive nature of the literature search, the immediate relevancy of the questions at hand to decision making, and the adoption of bias protection measures that included contacting the authors of the included studies. Limitations to the inferences presented in this report relate to the overall low quality of evidence due to the methodological limitations of the included studies, and by the imprecision and heterogeneity in the results. Also, this evidence is at high risk of publication and reporting biases, both of which are more likely when the evidence consists of mostly small RCTs and observational studies. Inferences should also be limited considering the frequent use of the surrogate outcome, prolactin level, as opposed to patient-important outcomes [25], such as loss of quality of life due to tumor-related and hypogonadal symptoms.


This systematic review and meta-analyses affirm the use of dopamine agonists in treating hyperprolactinemia and reducing associated morbidity. Cabergoline was found to be more effective than bromocriptine in achieving normoprolactinemia and resolving amenorrhea/oligomenorrhea and galactorrhea. Radiotherapy and surgery are efficacious in patients with resistance or intolerance to dopamine agonists.


This research was partially funded by the Endocrine Society.



Preferred reporting items for systematic reviews and meta-analyses


Randomized controlled trial


Relative risk


Weighted mean difference.


Authors’ Affiliations

Knowledge and Evaluation Research Unit, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Division of Preventive Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Endocrinology, Diabetes and Nutrition Unit, Hospital Universitari de Girona, Dr. Josep Trueta, Avinguda de França, Girona, 17007, Spain
Hospital Nacional de Geriatría y Gerontología, Caja Costarricense de Seguro Social, Avenue 8, San José, Costa Rica
Division of Endocrinology and Metabolism, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Mayo Clinic Libraries, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA


  1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006, 65: 265-273. 10.1111/j.1365-2265.2006.02562.x.View ArticleGoogle Scholar
  2. Gillam M, Molitch M, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev. 2006, 27: 485-534. 10.1210/er.2005-9998.PubMedView ArticleGoogle Scholar
  3. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: b2535-10.1136/bmj.b2535.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. ,,
  5. Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008, 93: 666-673.PubMedView ArticleGoogle Scholar
  6. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.PubMedView ArticleGoogle Scholar
  7. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327: 557-560. 10.1136/bmj.327.7414.557.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H: Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril. 1998, 70: 246-252. 10.1016/S0015-0282(98)00164-2.PubMedView ArticleGoogle Scholar
  9. Homburg R, West C, Brownell J, Jacobs HS: A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol. 1990, 32: 565-571. 10.1111/j.1365-2265.1990.tb00899.x.View ArticleGoogle Scholar
  10. Lappohn RE, van de Wiel HB, Brownell J: The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril. 1992, 58: 321-327.PubMedView ArticleGoogle Scholar
  11. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J: Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 1995, 24: 753-757.PubMedGoogle Scholar
  12. van der Heijden PF, de Wit W, Brownell J, Schoemaker J, Rolland R: CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol. 1991, 40: 111-118. 10.1016/0028-2243(91)90101-P.PubMedView ArticleGoogle Scholar
  13. Verhelst JA, Froud AL, Touzel R, Wass JA, Besser GM, Grossman AB: Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol. 1991, 125: 385-391.PubMedGoogle Scholar
  14. Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon M: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994, 331: 904-909. 10.1056/NEJM199410063311403.PubMedView ArticleGoogle Scholar
  15. Motazedian S, Babakhani L, Fereshtehnejad SM, Mojtahedi K: A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian J Med Res. 2010, 131: 670-674.PubMedGoogle Scholar
  16. Bahceci M, Sismanoglu A, Ulug U: Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol. 2010, 26: 505-508. 10.3109/09513591003632233.PubMedView ArticleGoogle Scholar
  17. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G: Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. 1998, 138: 286-293.Google Scholar
  18. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004, 19: 656-662. 10.1002/mds.20201.PubMedView ArticleGoogle Scholar
  19. Rascol O, Pathak A, Bagheri H, Montastruc JL: New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord. 2004, 19: 611-613. 10.1002/mds.20202.PubMedView ArticleGoogle Scholar
  20. Lafeber M, Stades AME, Valk GD, Cramer MJ, van Berkhout FT, Zelissen PMJ: Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur. 2010, 162: 667-675.Google Scholar
  21. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NM: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol. 2010, 73: 369-374. 10.1111/j.1365-2265.2010.03827.x.View ArticleGoogle Scholar
  22. Valassi E, Klibanski A, Biller BM: Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010, 95: 1025-1033. 10.1210/jc.2009-2095.PubMedView ArticleGoogle Scholar
  23. Glasziou P, Chalmers I, Rawlins M, McCulloch P: When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007, 334: 349-351. 10.1136/bmj.39070.527986.68.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M: Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008, 158: 11-18. 10.1530/EJE-07-0248.PubMedView ArticleGoogle Scholar
  25. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA: Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96: 273-288. 10.1210/jc.2010-1692.PubMedView ArticleGoogle Scholar
  26. Dekkers O, Lagro J, Burman P, Jørgensen J, Romijn J, Pereira A: Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010, 95: 43-51. 10.1210/jc.2009-1238.PubMedView ArticleGoogle Scholar
  27. Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR: Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011, 14: 259-265. 10.1007/s11102-010-0290-z.PubMedView ArticleGoogle Scholar
  28. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM: Patient-important outcomes in registered diabetes trials. JAMA. 2008, 299: 2543-2549. 10.1001/jama.299.21.2543.PubMedView ArticleGoogle Scholar
  29. Asano S, Ueki K, Suzuki I, Kirino T: Clinical features and medical treatment of male prolactinomas. Acta Neurochir. 2001, 143: 465-470. 10.1007/s007010170075.PubMedView ArticleGoogle Scholar
  30. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P: Prolactinomas and resistance to dopamine agonists. Horm Res. 1992, 38: 84-89. 10.1159/000182496.PubMedView ArticleGoogle Scholar
  31. Candrina R, Galli G, Bollati A, Pizzocolo G, Orlandini A, Gualandi GF, Giustina G: Results of combined surgical and medical therapy in patients with prolactin-secreting pituitary macroadenomas. Neurosurgery. 1987, 21: 894-897. 10.1227/00006123-198712000-00018.PubMedView ArticleGoogle Scholar
  32. Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G: Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm Res. 1995, 44: 222-228. 10.1159/000184630.PubMedView ArticleGoogle Scholar
  33. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001, 86: 5256-5261. 10.1210/jc.86.11.5256.PubMedView ArticleGoogle Scholar
  34. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G: Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab. 1998, 83: 807-813. 10.1210/jc.83.3.807.PubMedView ArticleGoogle Scholar
  35. Hildebrandt G, Bauer T, Stracke H, Fassbender WJ, Mueller HW, Agnoli AL, Federlin K, Roosen K: Surgery, dopamine agonist therapy of combined treatment–results in prolactinoma patients after a 12 month follow-up. Zentralbl Neurochir. 1992, 53: 123-134.PubMedGoogle Scholar
  36. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1996, 45: 299-303. 10.1046/j.1365-2265.1996.00824.x.View ArticleGoogle Scholar
  37. Mahmood IH, Al-Husaynei AJ, Mohamad SH: Comparative effects of bromocriptine and cabergoline on serum prolactin levels, liver and kidney function tests in hyperprolactinemic women. Pak J Med Sci. 2010, 26: 255-260.Google Scholar
  38. Mattei AM, Severini V, Crosignani PG: Natural history of hyperprolactinemia. Ann N Y Acad Sci. 1991, 626: 130-136. 10.1111/j.1749-6632.1991.tb37907.x.PubMedView ArticleGoogle Scholar
  39. Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A: Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol Res Pract. 1991, 187: 587-592. 10.1016/S0344-0338(11)80151-2.PubMedView ArticleGoogle Scholar
  40. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A: Primary medical therapy of micro- and macroprolactinomas in men.[see comment]. J Clin Endocrinol Metab. 2000, 85: 3053-3057. 10.1210/jc.85.9.3053.PubMedGoogle Scholar
  41. Rush S, Donahue B, Cooper P, Lee C, Persky M, Newall J: Prolactin reduction after combined therapy for prolactin macroadenomas. Neurosurgery. 1991, 28: 502-505. 10.1227/00006123-199104000-00003.PubMedView ArticleGoogle Scholar
  42. Samaan NA, Schultz PN, Leavens TA, Leavens ME, Lee YY: Pregnancy after treatment in patients with prolactinoma: operation versus bromocriptine. Am J Obstet Gynecol. 1986, 155: 1300-1305.PubMedView ArticleGoogle Scholar
  43. Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G: Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest. 1990, 13: 419-422.PubMedView ArticleGoogle Scholar
  44. Shih CJ, Tsou CK, Chiu WT, Tsai SH: Management of prolactin-secreting pituitary adenomas with surgery and bromocriptine. Southeast Asian J Surg. 1983, 6: 38-46.Google Scholar
  45. Sluijmer AV, Lappohn RE: Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992, 58: 72-77.PubMedView ArticleGoogle Scholar
  46. Torres I, Carral F, Vilchez F, Gavilán J, Aguilar M: Clinical, radiologic, and follow-up findings in patients with macroprolactinoma. Endocrinologist. 2006, 16: 241-244. 10.1097/ ArticleGoogle Scholar
  47. Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F: Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand. 2001, 80: 162-168. 10.1034/j.1600-0412.2001.080002162.x.PubMedView ArticleGoogle Scholar
  48. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994, 331: 904-909. 10.1056/NEJM199410063311403.PubMedView ArticleGoogle Scholar
  49. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS: Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol. 2005, 63: 26-31. 10.1111/j.1365-2265.2005.02293.x.View ArticleGoogle Scholar
  50. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F: Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest. 1999, 22: 354-359.PubMedView ArticleGoogle Scholar
  51. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammarota T, Camanni M, Camanni F: Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest. 1997, 20: 547-551.PubMedView ArticleGoogle Scholar
  52. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.[see comment]. N Engl J Med. 2003, 349: 2023-2033. 10.1056/NEJMoa022657.PubMedView ArticleGoogle Scholar
  53. Corenblum B, Taylor PJ: Idiopathic hyperprolactinemia may include a distinct entity with a natural history different from that of prolactin adenomas. Fertil Steril. 1988, 49: 544-546.PubMedView ArticleGoogle Scholar
  54. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A: The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf). 2000, 53: 53-60. 10.1046/j.1365-2265.2000.01016.x.View ArticleGoogle Scholar
  55. Eversmann T, Fahlbusch R, Rjosk HK, von Werder K: Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol (Copenh). 1979, 92: 413-427.Google Scholar
  56. Hancock KW, Scott JS, Lamb JT, Gibson RM, Chapman C: Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas. Br Med J (Clin Res Ed). 1985, 290: 117-118.View ArticleGoogle Scholar
  57. Johnston DG, Prescott RW, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB: Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med. 1983, 75: 868-874. 10.1016/0002-9343(83)90418-7.PubMedView ArticleGoogle Scholar
  58. Kharlip J, Salvatori R, Yenokyan G, Wand GS: Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.[see comment]. J Clin Endocrinol Metab. 2009, 94: 2428-2436. 10.1210/jc.2008-2103.PubMedPubMed CentralView ArticleGoogle Scholar
  59. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985, 313: 656-659. 10.1056/NEJM198509123131103.PubMedView ArticleGoogle Scholar
  60. Mattei AM, Ferrari C, Ragni G, Benco R, Picciotti MC, Rampini P, Caldara R, Crosignani PG: Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br J Obstet Gynaecol. 1984, 91: 244-250. 10.1111/j.1471-0528.1984.tb04761.x.PubMedView ArticleGoogle Scholar
  61. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G: Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab. 1985, 60: 764-772. 10.1210/jcem-60-4-764.PubMedView ArticleGoogle Scholar
  62. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997, 20: 537-546.PubMedView ArticleGoogle Scholar
  63. Passos VQ, Souza JJ, Musolino NR, Bronstein MD: Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002, 87: 3578-3582. 10.1210/jc.87.8.3578.PubMedView ArticleGoogle Scholar
  64. Tartagni M, Nicastri PL, Diaferia A, Di Gesu I, Loizzi P: Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine. Clin Exp Obstet Gynecol. 1995, 22: 301-306.PubMedGoogle Scholar
  65. van 't Verlaat JW, Croughs RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.[see comment]. Clin Endocrinol (Oxf). 1991, 34: 175-178. 10.1111/j.1365-2265.1991.tb00289.x.View ArticleGoogle Scholar
  66. Winkelmann W, Allolio B, Deuss U, Heesen D, Kaulen D: Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. Basic and Clinical Correlates. Edited by: Macleod RM, Thorner MO, Scapagnini U. 1985, Liviana Press, Padova, 817-822.Google Scholar
  67. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM: Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg. 2006, 104: 54-61. 10.3171/jns.2006.104.1.54.PubMedView ArticleGoogle Scholar
  68. Zarate A, Canales ES, Cano C, Pilonieta CJ: Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh). 1983, 104: 139-142.Google Scholar
  69. Al-Suleiman SA, Najashi S, Rahman J, Rahman MS: Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust N Z J Obstet Gynaecol. 1989, 29: 176-179. 10.1111/j.1479-828X.1989.tb01712.x.PubMedView ArticleGoogle Scholar
  70. Bergh T, Nillius J, Wide L: Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenh). 1978, 88: 435-451.Google Scholar
  71. Brue T, Lancranjan I, Louvet JP, Dewailly D, Roger P, Jaquet P: A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertil Steril. 1992, 57: 74-80.PubMedView ArticleGoogle Scholar
  72. Cannavo S, De Natale R, Curto L, Li Calzi L, Trimarchi F: Effectiveness of computer-assisted perimetry in the follow-up of patients with pituitary microadenoma responsive to medical treatment. Clin Endocrinol. 1992, 37: 157-161. 10.1111/j.1365-2265.1992.tb02300.x.View ArticleGoogle Scholar
  73. Chattopadhyay A, Bhansali A, Masoodi SR: Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary. 2005, 8: 147-154. 10.1007/s11102-005-5111-4.PubMedView ArticleGoogle Scholar
  74. Corenblum B, Taylor PJ: Long-term follow-up of hyperprolactinemic women treated with bromocriptine. Fertil Steril. 1983, 40: 596-599.PubMedView ArticleGoogle Scholar
  75. Espinos JJ, Rodriguez-Espinosa J, Webb SM, Calaf-Alsina J: Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril. 1994, 62: 926-931.PubMedView ArticleGoogle Scholar
  76. Essais O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, Zidi B, Ben Slama C: Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol. 2002, 63: 524-531.Google Scholar
  77. Falsetti L, Zanagnolo V, Gastaldi A: A retrospective study of idiopathic hyperprolactinemias. Curr Ther Res Clin Exp. 1988, 43: 1063-1072.Google Scholar
  78. Fletes Rabago VM, Torres Farias S, Dominguez Jimenez A, Padilla Ruiz R: [Alternative to bromocriptine (BEC) management in patients with prolactinoma and intolerance to oral BEC]. Ginecol Obstet Mex. 1991, 59: 283-288.PubMedGoogle Scholar
  79. Greenspan SL, Oppenheim DS, Klibanski A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1989, 110: 526-531.PubMedView ArticleGoogle Scholar
  80. Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G: Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years. Clin Endocrinol. 1993, 38: 165-176. 10.1111/j.1365-2265.1993.tb00989.x.View ArticleGoogle Scholar
  81. Holtkamp W, Nagel GA: Bromocriptine with chemotherapy resistant, metastatic breast cancer. Results of the AIO-Study GO-MC-BROMO 2/82. Onkologie. 1988, 11: 121-127. 10.1159/000216502.PubMedGoogle Scholar
  82. Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP: Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. J Endocrinol Invest. 1996, 19: 472-479.PubMedView ArticleGoogle Scholar
  83. Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I: Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas. Fertil Steril. 1993, 59: 980-987.PubMedView ArticleGoogle Scholar
  84. Lin SQ: Experiences with bromocriptine treatment of female infertility due to hyperprolactinemia. Zhonghua Fu Chan Ke Za Zhi. 1992, 27: 28-31.PubMedGoogle Scholar
  85. Moberg E, af Trampe E, Wersall J, Werner S: Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas. Neurosurgery. 1991, 29: 200-204. 10.1227/00006123-199108000-00005. discussion 204-205PubMedView ArticleGoogle Scholar
  86. Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F: Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol (Copenh). 1991, 125: 494-501.Google Scholar
  87. Merola B, Colao A, Caruso E, Sarnacchiaro F, Lancranjan I, Lombardi G, Schettini G: Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J Endocrinol Invest. 1992, 15: 173-176.PubMedView ArticleGoogle Scholar
  88. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985, 60: 698-705. 10.1210/jcem-60-4-698.PubMedView ArticleGoogle Scholar
  89. Mornex R, Orgiazzi J, Hugues B, Gagnaire JC, Claustrat B: Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab. 1978, 47: 290-295. 10.1210/jcem-47-2-290.PubMedView ArticleGoogle Scholar
  90. Moro M, Maraschini C, Toja P, Masala A, Alagna S, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F: Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res. 1991, 35: 137-141. 10.1159/000181889.PubMedView ArticleGoogle Scholar
  91. Paoletti AM, Cagnacci A, Mais V, Ajossa S, Guerriero S, Murgia C, Depau GF, Serra GG, Melis GB: Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections. Clin Exp Obstet Gynecol. 1994, 21: 124-128.PubMedGoogle Scholar
  92. Rasmussen C, Larsson SG, Bergh T: Long-term radiographic follow-up of the sella turcica in hyperprolactinaemic women. Aust N Z J Obstet Gynaecol. 1990, 30: 257-264. 10.1111/j.1479-828X.1990.tb03228.x.PubMedView ArticleGoogle Scholar
  93. Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I: Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol. 1990, 33: 161-169. 10.1111/j.1365-2265.1990.tb00479.x.View ArticleGoogle Scholar
  94. Skrabanek P, McDonald D, De Valera E: Plasma prolactin in amenorrhoea, infertility, and other disorders: A retrospective study of 608 patients. Ir J Med Sci. 1980, 149: 236-245. 10.1007/BF02939147.PubMedView ArticleGoogle Scholar
  95. Spark RF, Baker R, Bienfang DC, Bergland R: Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?. JAMA. 1982, 247: 311-316. 10.1001/jama.1982.03320280031025.PubMedView ArticleGoogle Scholar
  96. Thorner MO, Besser GM: Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol Suppl. 1978, 216: 131-146.Google Scholar
  97. Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N: Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Clin Endocrinol. 1995, 42: 593-599. 10.1111/j.1365-2265.1995.tb02685.x.View ArticleGoogle Scholar
  98. van 't Verlaat JW, Croughs RJ, Hendriks MJ, Bosma NJ, Nortier JW, Thijssen JH: Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Acta Endocrinol (Copenh). 1986, 112: 487-493.Google Scholar
  99. Walsh JP, Pullan PT: Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med. 1997, 27: 385-390. 10.1111/j.1445-5994.1997.tb02196.x.PubMedView ArticleGoogle Scholar
  100. Wass JA, Williams J, Charlesworth M, Kingsley DP, Halliday AM, Doniach I, Rees LH, McDonald WI, Besser GM: Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed). 1982, 284: 1908-1911. 10.1136/bmj.284.6333.1908.View ArticleGoogle Scholar
  101. Weingrill CO, Mussio W, Moraes CR, Portes E, Castro RC, Lengyel AM: Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. Fertil Steril. 1992, 57: 331-335.PubMedView ArticleGoogle Scholar
  102. Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH: Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol. 2011, 104: 195-204. 10.1007/s11060-010-0459-3.PubMedView ArticleGoogle Scholar
  103. Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S: Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010, 131: 530-535.PubMedGoogle Scholar
  104. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996, 81: 2338-2343. 10.1210/jc.81.6.2338.PubMedGoogle Scholar
  105. Bolko P, Jaskula M, Wasko R, Wolun M, Sowinski J: The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Polskie Archiwum Medycyny Wewnetrznej. 2003, 109: 489-495.PubMedGoogle Scholar
  106. Buyukbayrak EE, Karageyim Karsidag AY, Kars B, Balcik O, Pirimoglu M, Unal O, Turan C: Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Arch Gynecol Obstet. 2010, 282: 561-566. 10.1007/s00404-010-1562-6.PubMedView ArticleGoogle Scholar
  107. Cho E-H, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim M-S: Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci. 2009, 24: 874-878. 10.3346/jkms.2009.24.5.874.PubMedPubMed CentralView ArticleGoogle Scholar
  108. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G: Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 1989, 69: 725-728. 10.1210/jcem-69-4-725.PubMedView ArticleGoogle Scholar
  109. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997, 82: 3574-3579. 10.1210/jc.82.11.3574.PubMedView ArticleGoogle Scholar
  110. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000, 85: 2247-2252. 10.1210/jc.85.6.2247.PubMedGoogle Scholar
  111. Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G: Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab. 2004, 89: 2770-2775. 10.1210/jc.2003-032055.PubMedView ArticleGoogle Scholar
  112. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G: Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004, 89: 1704-1711. 10.1210/jc.2003-030979.PubMedView ArticleGoogle Scholar
  113. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C: Giant prolactinomas in men: Efficacy of cabergoline treatment. Clin Endocrinol. 2003, 58: 662-670. 10.1046/j.1365-2265.2003.01770.x.View ArticleGoogle Scholar
  114. De Bellis A, Colao A, Savoia A, Coronella C, Pasquali D, Conte M, Pivonello R, Bellastella A, Sinisi AA, Bizzarro A, Lombardi G, Bellastella G: Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies. Clin Endocrinol. 2008, 69: 285-291. 10.1111/j.1365-2265.2008.03200.x.View ArticleGoogle Scholar
  115. De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A: The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol. 2006, 64: 307-313. 10.1111/j.1365-2265.2006.02461.x.View ArticleGoogle Scholar
  116. Delgrange E, Maiter D, Donckier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. 1996, 134: 454-456.Google Scholar
  117. Ferrari C, Paracchi A, Mattei AM, De Vincentiis S, D'Alberton A, Crosignani P: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992, 126: 489-494.Google Scholar
  118. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol. 1997, 46: 409-413. 10.1046/j.1365-2265.1997.1300952.x.View ArticleGoogle Scholar
  119. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.[see comment]. J Clin Endocrinol Metab. 2008, 93: 4721-4727. 10.1210/jc.2007-2758.PubMedView ArticleGoogle Scholar
  120. Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S-, Okada Y, Hori T: Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010, 95: 2672-2679. 10.1210/jc.2009-2605.PubMedView ArticleGoogle Scholar
  121. Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T: Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary. 2000, 2: 277-281. 10.1023/A:1009913200542.PubMedView ArticleGoogle Scholar
  122. Raverot G, Jacob M, Jouanneau E, Delemer B, Vighetto A, Pugeat M, Borson-Chazot F: Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol. 2009, 70: 588-592. 10.1111/j.1365-2265.2008.03364.x.View ArticleGoogle Scholar
  123. Shimon I, Benbassat C, Hadani M: Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur. 2007, 156: 225-231.Google Scholar
  124. Sinha S, Sharma BS, Mahapatra AK: Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases. Neurol India. 2011, 59: 532-536. 10.4103/0028-3886.84332.PubMedView ArticleGoogle Scholar
  125. Walia R, Bhansali A, Dutta P, Khandelwal N, Sialy R, Bhadada S: Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. Indian J Med Res. 2011, 134: 314-319.PubMedPubMed CentralGoogle Scholar
  126. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E: The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol. 1993, 39: 323-329. 10.1111/j.1365-2265.1993.tb02372.x.View ArticleGoogle Scholar
  127. Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, Zarrilli S, Merola B, Lombardi G: Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur. 1996, 135: 548-552.Google Scholar
  128. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM: Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol. 1991, 34: 25-29. 10.1111/j.1365-2265.1991.tb01731.x.View ArticleGoogle Scholar
  129. Kvistborg A, Halse J, Bakke S, Bjoro T, Hansen E, Djoseland O, Brownell J, Jervell J: Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh). 1993, 128: 301-307.Google Scholar
  130. Merola B, Sarnacchiaro F, Colao A, Disomma C, Disarno A, Landi ML, Marzullo P, Panza N, Battista C, Lombardi G: CV-205-502 in the treatment of tumoral and nontumoral hyperprolactinemic states. Biomed Pharmacother. 1994, 48: 167-174. 10.1016/0753-3322(94)90105-8.PubMedView ArticleGoogle Scholar
  131. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P: Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur. 1996, 135: 413-420.Google Scholar
  132. Newman CB, Hurley AM, Kleinberg DL: Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol. 1989, 31: 391-400. 10.1111/j.1365-2265.1989.tb01263.x.View ArticleGoogle Scholar
  133. Nickelsen T, Jungmann E, Althoff P, Schummdraeger PM, Usadel KH: Treatment of macroprolactinoma with the new potent nonergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary-function, and the renin-aldosterone system- results of a clinical long-term study. Arzneimittelforschung. 1993, 43: 421-425.PubMedGoogle Scholar
  134. Rasmussen C, Bergh T, Wide L, Brownell J: Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia. Clin Endocrinol. 1988, 29: 271-279. 10.1111/j.1365-2265.1988.tb01225.x.View ArticleGoogle Scholar
  135. Rohmer V, Freneau E, Morange I, Simonetta C: Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris). 2000, 61: 411-417.Google Scholar
  136. Shoham Z, Homburg R, Jacobs HS: CV 205–502–effectiveness, tolerability, and safety over 24-month study. Fertil Steril. 1991, 55: 501-506.PubMedView ArticleGoogle Scholar
  137. van der Heijden PF, Lappohn RE, Corbey RS, de Goeij WB, Brownell J, Rolland R: The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. Fertil Steril. 1989, 52: 574-579.PubMedView ArticleGoogle Scholar
  138. van der Lely AJ, Brownell J, Lamberts SW: The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab. 1991, 72: 1136-1141. 10.1210/jcem-72-5-1136.PubMedView ArticleGoogle Scholar
  139. Vance ML, Lipper M, Klibanski A, Biller BMK, Samaan NA, Molitch ME: Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med. 1990, 112: 668-673.PubMedView ArticleGoogle Scholar
  140. Vilar L, Burke CW: Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.[see comment]. Clin Endocrinol. 1994, 41: 821-826. 10.1111/j.1365-2265.1994.tb02799.x.View ArticleGoogle Scholar
  141. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL: Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab. 2000, 85: 8-13. 10.1210/jc.85.1.8.PubMedView ArticleGoogle Scholar
  142. Jaspers C, Benker G, Reinwein D: Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: First results. Clin Investig. 1994, 72: 451-456.PubMedView ArticleGoogle Scholar
  143. Orrego JJ, Chandler WF, Barkan AL: Pergolide as primary therapy for macroprolactinomas. Pituitary. 2000, 3: 251-256. 10.1023/A:1012836331506.PubMedView ArticleGoogle Scholar
  144. Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R: Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary. 2002, 5: 243-246. 10.1023/A:1025377816769.PubMedView ArticleGoogle Scholar
  145. Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R: Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest. 1980, 3: 405-414.PubMedView ArticleGoogle Scholar
  146. Jezkova J, Hana V, Krsek M, Weiss V, Vladyka V, Liscak R, Vymazal J, Pecen L, Marek J: Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol. 2009, 70: 732-741. 10.1111/j.1365-2265.2008.03384.x.View ArticleGoogle Scholar
  147. Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW: Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2000, 93: 10-13.PubMedGoogle Scholar
  148. Pouratian N, Sheehan J, Jagannathan J, Laws ER, Steiner L, Vance ML: Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006, 59: 255-266. 10.1227/01.NEU.0000223445.22938.BD. discussion 255-266PubMedView ArticleGoogle Scholar
  149. Sun DQ, Cheng JJ, Frazier JL, Batra S, Wand G, Kleinberg LR, Rigamonti D, Quinones-Hinojosa A, Salvatori R, Lim M: Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2010, 34: 181-189.PubMedView ArticleGoogle Scholar
  150. Tsagarakis S, Grossman A, Plowman PN, Jones AE, Touzel R, Rees LH, Wass JA, Besser GM: Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol. 1991, 34: 399-406. 10.1111/j.1365-2265.1991.tb00312.x.View ArticleGoogle Scholar
  151. Yoon SC, Suh TS, Jang HS, Chung SM, Kim YS, Ryu MR, Choi KH, Son HY, Kim MC, Shinn KS: Clinical results of 24 pituitary macroadenomas with linac-based stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 1998, 41: 849-853. 10.1016/S0360-3016(98)00124-2.PubMedView ArticleGoogle Scholar
  152. Zhang N, Pan L, Dai J, Wang B, Wang E, Zhang W, Cai P: Gamma Knife radiosurgery as a primary surgical treatment for hypersecreting pituitary adenomas. Stereotact Funct Neurosurg. 2000, 75: 123-128. 10.1159/000048393.PubMedView ArticleGoogle Scholar
  153. Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M: External Radiotherapy of Pituitary Adenomas. Int J Radiat Oncol Biol Phys. 1995, 33: 307-314. 10.1016/0360-3016(95)00071-6.PubMedView ArticleGoogle Scholar
  154. Kelly WF, Mashiter K, Doyle FH, Banks LM, Joplin GF: Treatment of prolactin-secreting pituitary tumours in young women by needle implantation of radioactive yttrium. Q J Med. 1978, 47: 473-493.PubMedGoogle Scholar
  155. Littley MD, Shalet SM, Reid H, Beardwell CG, Sutton ML: The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med. 1991, 81: 985-998. 10.1093/qjmed/81.3.985.PubMedView ArticleGoogle Scholar
  156. Rudoler SB, Ruffer JE, Gennarelli TA, Savino PJ, Fowble BF: Long-term results of radiotherapy for prolactin-secreting pituitary macroadenomas. Radiat Oncol Investig. 1996, 4: 185-191. 10.1002/(SICI)1520-6823(1996)4:4<185::AID-ROI6>3.0.CO;2-U.View ArticleGoogle Scholar
  157. Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF, Pollock BE: Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. 2010, 74: 147-152. 10.1016/j.wneu.2010.05.007.PubMedView ArticleGoogle Scholar
  158. Amar AP, Couldwell WT, Chen JCT, Weiss MH: Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002, 97: 307-314. 10.3171/jns.2002.97.2.0307.PubMedView ArticleGoogle Scholar
  159. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW: Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011, 14: 222-230. 10.1007/s11102-010-0283-y.PubMedView ArticleGoogle Scholar
  160. Barbarino A, De Marinis L, Anile C, Menini E, Merlini G, Maira G: Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism. 1982, 31: 1100-1104. 10.1016/0026-0495(82)90159-7.PubMedView ArticleGoogle Scholar
  161. Charpentier G, de Plunkett T, Jedynak P, Peillon F, Le Gentil P, Racadot J, Visot A, Derome P: Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Horm Res. 1985, 22: 222-227. 10.1159/000180098.PubMedView ArticleGoogle Scholar
  162. Dusick JR, Fatemi N, Mattozo C, McArthur D, Cohan P, Wang C, Swerdloff RS, Kelly DF: Pituitary function after endonasal surgery for nonadenomatous parasellar tumors: Rathke's cleft cysts, craniopharyngiomas, and meningiomas. Surg Neurol. 2008, 70: 482-490. 10.1016/j.surneu.2008.03.027.PubMedView ArticleGoogle Scholar
  163. Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, Wang C, Swerdloff RS, Kelly DF: Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008, 63: 709-718. 10.1227/01.NEU.0000325725.77132.90.PubMedView ArticleGoogle Scholar
  164. Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB: Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab. 1996, 81: 1711-1719. 10.1210/jc.81.5.1711.PubMedGoogle Scholar
  165. Gokalp HZ, Deda H, Attar A, Ugur HC, Arasil E, Egemen N: The neurosurgical management of prolactinomas. J Neurosurg Sci. 2000, 44: 128-132.PubMedGoogle Scholar
  166. Guidetti B, Fraioli B, Cantore GP: Results of surgical management of 319 pituitary adenomas. Acta Neurochir. 1987, 85: 117-124. 10.1007/BF01456107.PubMedView ArticleGoogle Scholar
  167. Hamilton DK, Vance ML, Boulos PT, Laws ER: Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005, 8: 53-60. 10.1007/s11102-005-5086-1.PubMedView ArticleGoogle Scholar
  168. Hirohata T, Uozumi T, Mukada K, Arita K, Kurisu K, Yano T, Takechi A, Onda J: Influence of pregnancy on the serum prolactin level following prolactinoma surgery. Acta Endocrinol (Copenh). 1991, 125: 259-267.Google Scholar
  169. Laws ER, Fode NC, Redmond MJ: Transsphenoidal surgery following unsuccessful prior therapy. An assessment of benefits and risks in 158 patients. J Neurosurg. 1985, 63: 823-829. 10.3171/jns.1985.63.6.0823.PubMedView ArticleGoogle Scholar
  170. Maira G, Anile C, De Marinis L, Barbarino A: Prolactin-secreting adenomas: Surgical results and long-term follow-up. Neurosurgery. 1989, 24: 736-743. 10.1227/00006123-198905000-00013.PubMedView ArticleGoogle Scholar
  171. Massoud F, Serri O, Hardy J, Somma M, Beauregard H: Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol. 1996, 45: 341-346. 10.1016/0090-3019(95)00430-0.PubMedView ArticleGoogle Scholar
  172. Nakagawa H, Iwatsuki K, Yamada M, Hagiwara Y, Moriuchi S, Kadota T: Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment. Neurol Res. 2001, 23: 691-696. 10.1179/016164101101199199.PubMedView ArticleGoogle Scholar
  173. Pandey P, Ojha BK, Mahapatra AK: Pediatric pituitary adenoma: A series of 42 patients. J Clin Neurosci. 2005, 12: 124-127. 10.1016/j.jocn.2004.10.003.PubMedView ArticleGoogle Scholar
  174. Qu X, Wang M, Wang GD, Han T, Mou CZ, Han LZ, Jiang M, Qu YM, Zhang MA, Pang Q, Xu GM: Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur. 2011, 164: 499-504.Google Scholar
  175. Rawe SE, Williamson HO, Levine JH, Phansey SA, Hungerford D, Adkins WY: Prolactinomas: surgical therapy, indications and results. Surg Neurol. 1980, 14: 161-167.PubMedGoogle Scholar
  176. Saitoh Y, Mori S, Arita N, Nagatani M, Hayakawa T, Koizumi K, Tanizawa O, Uozumi T, Mogami H: Treatment of prolactinoma based on the results of transsphenoidal operations. Surg Neurol. 1986, 26: 338-344. 10.1016/0090-3019(86)90133-3.PubMedView ArticleGoogle Scholar
  177. Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea ML, Delfini R: Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol. 2007, 68: 513-518. 10.1016/j.surneu.2007.05.057.PubMedView ArticleGoogle Scholar
  178. Scamoni C, Balzarini C, Crivelli G, Dorizzi A: Treatment and long-term follow-up results of prolactin secreting pituitary adenomas. J Neurosurg Sci. 1991, 35: 9-16.PubMedGoogle Scholar
  179. Shen CC, Wang YC, Wei-Shan H, Chang CS, Sun MH: Endoscopic endonasal transsphenoidal surgery for pituitary tumors. Chinese Med J (Taipei). 2000, 63: 301-310.Google Scholar
  180. Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M: The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.[see comment]. Clin Endocrinol. 1996, 44: 711-716. 10.1046/j.1365-2265.1996.738559.x.View ArticleGoogle Scholar
  181. Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF: Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Endocrinol. 1992, 36: 35-44. 10.1111/j.1365-2265.1992.tb02900.x.View ArticleGoogle Scholar
  182. Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E: Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir. 2003, 145: 935-940. 10.1007/s00701-003-0134-y. discussion 940-931PubMedView ArticleGoogle Scholar
  183. Zhang HW, Sun W, Yang J, Yan CX, Yu CJ: Diagnosis and treatment of pituitary microadenoma: report of 80 cases. Neurol Res. 2008, 30: 587-593. 10.1179/174313208X310287.PubMedView ArticleGoogle Scholar
  184. Jamjoom ZAB, Malabarey T, Jamjoom AHB, Sulimani R, Rahman NU, Sadiq S: Problems in the management of large prolactin-secreting pituitary adenomas. Saudi Med J. 1995, 16: 119-125.Google Scholar
  185. Saeki N, Nakamura M, Sunami K, Yamaura A: Surgical indication after bromocriptine therapy on giant prolactinomas: Effects and limitations of the medical treatment. Endocr J. 1998, 45: 529-537. 10.1507/endocrj.45.529.PubMedView ArticleGoogle Scholar
  186. Thompson CJ, Tam NNC, Joyce JM, Leav I, Ho SM: Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in noble rats and response to the antiestrogen ICI 182,780. Endocrinology. 2002, 143: 2093-2105. 10.1210/en.143.6.2093.PubMedGoogle Scholar
  187. Thomson JA, Davies DL, McLaren EH, Teasdale GM: Ten year follow up of microprolactinoma treated by transsphenoidal surgery. Br Med J. 1994, 309: 1409-1410. 10.1136/bmj.309.6966.1409.View ArticleGoogle Scholar
  188. Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T: Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol. 2000, 53: 211-219. 10.1016/S0090-3019(00)00171-3.PubMedView ArticleGoogle Scholar
  189. Rush S, Cooper PR: Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Int J Radiat Oncol Biol Phys. 1997, 37: 1031-1034. 10.1016/S0360-3016(96)00586-X.PubMedView ArticleGoogle Scholar
  190. Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE: The long-term effects of pregnancy and bromocriptine treatment on prolactinomas–the value of radiologic studies. Early Pregnancy. 1997, 3: 306-311.PubMedGoogle Scholar
  191. Berinder K, Hulting AL, Granath F, Hirschberg AL, Akre O: Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group. Clin Endocrinol. 2007, 67: 393-397. 10.1111/j.1365-2265.2007.02897.x.View ArticleGoogle Scholar
  192. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL: Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol. 2008, 68: 66-71. 10.1111/j.1365-2265.2007.03000.x.View ArticleGoogle Scholar
  193. Cristiani P, De March A, Bulletti C: Follow-up of 17 hyperprolactinemic pregnant women by plasma prolactin levels and pituitary politomograms. J Gynaecol Endocrinol. 1985, 1: 48-51.Google Scholar
  194. Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P: Is pregnancy the best treatment for hyperprolactinaemia?. Hum Reprod. 1989, 4: 910-912.PubMedGoogle Scholar
  195. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G: Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol. 1992, 44: 175-180. 10.1016/0028-2243(92)90094-F.PubMedView ArticleGoogle Scholar
  196. Godo G, Koloszar S, Szilagyi I, Daru J, Sas M: Experience relating to pregnancy, lactation, and the afterweaning condition of hyperprolactinemic patients treated with bromocriptine. Fertil Steril. 1989, 51: 529-531.PubMedView ArticleGoogle Scholar
  197. Holmgren U, Bergstrand G, Hagenfeldt K, Werner S: Women with prolactinoma–effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh). 1986, 111: 452-459.Google Scholar
  198. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. [see comment]. Clin Endocrinol (Oxf). 1996, 45: 299-303. 10.1046/j.1365-2265.1996.00824.x.View ArticleGoogle Scholar
  199. Karunakaran S, Page RC, Wass JA: The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001, 54: 295-300. 10.1046/j.1365-2265.2001.01190.x.View ArticleGoogle Scholar
  200. Kelly WF, Doyle FH, Mashiter K, Banks LM, Gordon H, Joplin GF: Pregnancies in women with hyperprolactinaemia: clinical course and obstetric complications of 41 pregnancies in 27 women. Br J Obstet Gynaecol. 1979, 86: 698-705. 10.1111/j.1471-0528.1979.tb11269.x.PubMedView ArticleGoogle Scholar
  201. Kupersmith MJ, Rosenberg C, Kleinberg D: Visual loss in pregnant women with pituitary adenomas.[see comment]. Ann Intern Med. 1994, 121: 473-477.PubMedView ArticleGoogle Scholar
  202. Rasmussen C, Bergh T, Nillius SJ, Wide L: Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Fertil Steril. 1985, 44: 31-34.PubMedView ArticleGoogle Scholar
  203. Rossi AM, Vilska S, Heinonen PK: Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 1995, 63: 143-146. 10.1016/0301-2115(95)02257-0.PubMedView ArticleGoogle Scholar
  204. Woodhouse NJ, Niles N, McDonald D, McCorkell S: Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal. Horm Res. 1985, 21: 1-9. 10.1159/000180019.PubMedView ArticleGoogle Scholar
  205. Zarate A, Canales ES, Alger M, Forsbach G: The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol. 1979, 92: 407-412.PubMedGoogle Scholar


© Wang et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.